LT Investors Should Buy Sarepta Therapeutics Inc (SRPT): Roth

LT Investors Should Buy Sarepta Therapeutics Inc (SRPT): Roth

In a research note published yesterday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a $34 price target following the company’s most recent update on their progress where 144-week data showed waning of eteplirsen impact.

With regards to the data showed Chattopadhyay wrote, “We don’t believe it is the patient’s age at week-144 we should focus on, but the age of treatment initiation, which was 9.79 years. In our opinion, these boys had significant disease burden to show prolonged treatment benefit. Based on eteplirsen’s safety profile and the impact on disease stabilization, we believe that accelerated approval is likely”.

Chattopadhyay continued, “Eteplirsen is the first generation exon skipping compound, which was designed to stabilize patients for as long as possible, which in our opinion, it has amply demonstrated in older patients for over three years. Full clarity into the data should become available at the WMS Congress during the second week of October. We believe the next generation of peptide-modified exon skipping candidates are likely to take this a step further by increased permeability into appropriate cells, including the cardiomyocytes and the diaphragm”. She went on to say that “For long-term investors, we would recommend buying Sarepta Therapeutics Inc (NASDAQ:SRPT) at current levels as we continue to expect accelerated approval during 2H- 2015”.

Q2 2022 Hedge Fund Letters Database Now Live!

Hedge funds HFMQ2 2022 hedge fund letters database is now up. See what stocks top hedge funds are selling, what they are buying, what positions they are hiring for, what their investment process is, their returns and much more! This page is updated frequently, VERY FREQUENTLY, daily, or sometimes multiple times a day. As we get new Read More

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform analyst Debjit Chattopadhyay has a 7.9% average return and a 53.8% success rate. Chattopadhyay has a -11.8% average return when recommending Sarepta Therapeutics Inc (NASDAQ:SRPT), and is ranked #1290 out of 3190 analysts.


Updated on

TipRanks was founded in 2012 with the goal of giving power back to the individual investor. Our hope is that by making analyst performance data easily available and highly visible to the investing public, TipRanks will not just help save others from our investing mistakes, but will also bring back accountability, objectivity, and transparency to the business of stock picking and analyst reports. TipRanks is proudly unaffiliated with any investment firm.
Previous article T-Mobile Inc (TMUS) Up on Iliad Bid; Sprint Corporation (S) Down
Next article Warren Buffett Gives His Investing Advice To A Teen

No posts to display